SERVECTOR a raipd acting antidepressent.

Amineptine

From Wikipedia, the free encyclopedia

Jump to navigationJump to search

Amineptine

Clinical data
Trade names	Survector, others
Synonyms	S-1694
Routes of administration	Oral
ATC code	N06AA19 (WHO)
Legal status
Legal status	AU: Unscheduled CA: Schedule III DE: Anlage II (Authorized trade only, not prescriptible) UK: Class C UN: Narcotic Schedule II
Pharmacokinetic data
Metabolism	Hepatic
Elimination half-life	Amineptine: 0.8–1.0 hours[1][2] Metabolite: 1.5–2.5 hours[1][2]
Excretion	Renal
Identifiers
IUPAC name[show] 7-[(10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5-yl)amino]heptanoic acid
CAS Number	57574-09-1 Y
PubChem CID	34870
DrugBank	DB04836 Y
ChemSpider	32091 Y
UNII	27T1I13L6G
KEGG	D07335 Y
ChEBI	CHEBI:32499 Y
ChEMBL	CHEMBL418995 Y
ECHA InfoCard	100.055.271
Chemical and physical data
Formula	C22H28NO2
Molar mass	338.4653 g/mol
3D model (JSmol)	Interactive image
SMILES[show] O=C(CCCCCCNC1C2=C(CCC3=C1C=CC=C3)C=CC=C2)O
InChI[show] InChI=1S/C22H27NO2/c24-21(25)13-3-1-2-8-16-23-22-19-11-6-4-9-17(19)14-15-18-10-5-7-12-20(18)22/h4-7,9-12,22-23H,1-3,8,13-16H2,(H,24,25) Y Key:ONNOFKFOZAJDHT-UHFFFAOYSA-N Y
(verify)

Amineptine, sold under the brand name Survector among others, is an atypical antidepressant of the tricyclic antidepressant (TCA) family.^[3][4] It acts as a selective and mixed dopamine reuptake inhibitor and releasing agent, and to a lesser extent as a norepinephrine reuptake inhibitor.^[3][4]
Amineptine was developed by the French Society of Medical research in the 1960s.^[5] Introduced in France in 1978 by the pharmaceutical company Servier,^[6] amineptine soon gained a reputation for abuse due to its short-lived, but pleasant, stimulant effect experienced by some patients. (This is to be distinguished from its antidepressant effect, which appears in approximately seven days after commencing treatment.)
After its release into the European market, cases of hepatotoxicity emerged, some serious. This, along with the potential for abuse, led to the suspension of the French marketing authorization for Survector in 1999.^[7]
Amineptine was never approved by the U.S. Food and Drug Administration (FDA) for marketing in the United States, meaning that it is not legal to market or sell amineptine for any medical uses in the U.S.

Contents

 [hide] 
After Note: To me it is for major depressive period before it gets too late and needs E.C.T because it maybe habit forming . I cannot know it is true or not as I am not a Doctor.